STRIASCAN

This brand name is authorized in Austria, Croatia, Estonia, France, Ireland, Italy, Lithuania, Poland, Spain, UK.

Active ingredients

The drug STRIASCAN contains one active pharmaceutical ingredient (API):

1	Ioflupane ¹²³I UNII 3MM99T8R5Q - IOFLUPANE I-123
	Ioflupane ¹²³I is a radiopharmaceutical indicated for striatal dopamine transporter visualization using single photon emission computed tomography (SPECT) brain imaging to assist in the evaluation of adult patients with suspected Parkinsonian syndromes (PS).
	Read more about Ioflupane ¹²³I

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
STRIASCAN Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
V09AB03	Iodine ioflupane (123I)	V Various → V09 Diagnostic radiopharmaceuticals → V09A Central nervous system → V09AB Iodine (123I) compounds
Discover more medicines within V09AB03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1798690, 1798702
ES	Centro de información online de medicamentos de la AEMPS	1191372001
FR	Base de données publique des médicaments	69037684
GB	Medicines & Healthcare Products Regulatory Agency	395659
IT	Agenzia del Farmaco	048078012, 048078024
LT	Valstybinė vaistų kontrolės tarnyba	1088129, 1088130
PL	Rejestru Produktów Leczniczych	100423230